Researchers propose widespread banking of stool samples for autologous faecal microbiota transplant later in life

Researchers from Harvard Medical School and Brigham and Women's Hospital (BWH) have proposed that having individuals bank samples of people’s own gut microbiota when they are young and healthy for potential use later in life in an autologous faecal microbiota transplant (FMT). The findings were reported in the paper, ‘Rejuvenating the human gut microbiome', published in Trends in Molecular Medicine.

New classification system proposed for CRC to guide treatment and clinical trials

A team of clinician-scientists and scientists, led by the National Cancer Centre Singapore (NCCS) and A*STAR's Genome Institute of Singapore (GIS) together with collaborators in Europe and South Korea, who used single cell techniques to uncover a central dichotomy for colorectal cancer cells, have proposed an update of the classification system for the disease.

Researchers examine key to CRC relapse after chemotherapy

Researchers led by Dr Eduard Batlle, ICREA researcher and head of the Colorectal Cancer Laboratory at IRB Barcelona, have found that some tumour cells remain in a latent state and, after chemotherapy, they are reactivated, thus causing relapse. Their findings were featured in the paper, ‘Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy’, published in Nature Cancer.

Outcomes of natural orifice specimen extraction surgery (NOSES) for CRC

With the rapid development of minimally invasive surgery for the treatment of colorectal diseases, novel surgical techniques aiming at reducing surgical trauma have become frequently discussed issues. By avoiding auxiliary abdominal incision for specimen extraction, natural orifice specimen extraction surgery (NOSES), including transvaginal specimen extraction (TVSE) and transanal specimen extraction (TASE), is thought to be one of the least invasive options in the treatment of colorectal cancer (CRC).

Directing chemotherapy to ctDNA-positive patients reduces overall chemotherapy use

A study showed that circulating tumour DNA (ctDNA) - genetic material shed from tumours into the bloodstream - can identify stage II colon cancer patients who can most benefit from chemotherapy following surgery and spare other patients the need for this form of treatment.